Nippon Shinyaku Co. Ltd. has divulged quinazoline compounds acting as microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors reported to be useful for the treatment of irritable bowel syndrome, psoriasis, arthritis, bacterial infection, systemic lupus erythematosus, pancreatitis, asthma and chronic obstructive pulmonary disease, among others.